Literature DB >> 15601599

In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus.

Xinyu Wang1, Diana Dow-Edwards, Virginia Anderson, Howard Minkoff, Yasmin L Hurd.   

Abstract

BACKGROUND: Marijuana (Cannabis sativa) is the illicit drug most used by pregnant women, and behavioral and cognitive impairments have been documented in cannabis-exposed offspring. Despite the extensive use of marijuana, very limited information exists as to the consequences of prenatal cannabis exposure on the developing human brain.
METHODS: We optimized an in situ hybridization histochemistry technique to visualize mRNA expression in midgestation (weeks 18-22) human fetal specimens from mothers with and without documented evidence of cannabis use during pregnancy. The cannabinoid receptor type 1 (CB(1)) and major dopamine receptor subtypes, D(1) and D(2), were examined in the striatum and mesocorticolimbic structures (amygdala and hippocampus).
RESULTS: Adjusting for various covariates, we found a specific reduction, particularly in male fetuses, of the D(2) mRNA expression levels in the amygdala basal nucleus in association with maternal marijuana use. The reduction was positively correlated with the amount of maternal marijuana intake during pregnancy. No significant cannabis-related alterations were detected in the hippocampus or caudal striatum for the D(2), D(1), and CB(1) mRNA levels, although alcohol showed significant contribution to striatal D(1)/D(2) expression.
CONCLUSIONS: These human fetal findings suggest that in utero cannabis exposure may impair distinct mesocorticolimbic neural systems that regulate emotional behavior.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601599     DOI: 10.1016/j.biopsych.2004.10.015

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  39 in total

1.  Secretagogin is a Ca2+-binding protein identifying prospective extended amygdala neurons in the developing mammalian telencephalon.

Authors:  Jan Mulder; Lauren Spence; Giuseppe Tortoriello; Jennifer A Dinieri; Mathias Uhlén; Bo Shui; Michael I Kotlikoff; Yuchio Yanagawa; Fabienne Aujard; Tomas Hökfelt; Yasmin L Hurd; Tibor Harkany
Journal:  Eur J Neurosci       Date:  2010-06-07       Impact factor: 3.386

2.  Neuroimaging of prenatal drug exposure.

Authors:  Diana L Dow-Edwards; Helene Benveniste; Marylou Behnke; Emmalee S Bandstra; Lynn T Singer; Yasmin L Hurd; L R Stanford
Journal:  Neurotoxicol Teratol       Date:  2006 May-Jun       Impact factor: 3.763

3.  Associations of first trimester co-use of tobacco and Cannabis with prenatal immune response and psychosocial well-being.

Authors:  Kristin Ashford; Amanda Fallin-Bennett; Andrea McCubbin; Amanda Wiggins; Sheila Barnhart; Josh Lile
Journal:  Neurotoxicol Teratol       Date:  2019-03-29       Impact factor: 3.763

Review 4.  Molecular model of cannabis sensitivity in developing neuronal circuits.

Authors:  Erik Keimpema; Ken Mackie; Tibor Harkany
Journal:  Trends Pharmacol Sci       Date:  2011-07-13       Impact factor: 14.819

Review 5.  Cannabis and the Developing Brain: Insights into Its Long-Lasting Effects.

Authors:  Yasmin L Hurd; Olivier J Manzoni; Mikhail V Pletnikov; Francis S Lee; Sagnik Bhattacharyya; Miriam Melis
Journal:  J Neurosci       Date:  2019-10-16       Impact factor: 6.167

Review 6.  Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome.

Authors:  Didier Jutras-Aswad; Jennifer A DiNieri; Tibor Harkany; Yasmin L Hurd
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

Review 7.  Cannabis, the pregnant woman and her child: weeding out the myths.

Authors:  S C Jaques; A Kingsbury; P Henshcke; C Chomchai; S Clews; J Falconer; M E Abdel-Latif; J M Feller; J L Oei
Journal:  J Perinatol       Date:  2014-01-23       Impact factor: 2.521

8.  Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring.

Authors:  Jennifer A DiNieri; Xinyu Wang; Henrietta Szutorisz; Sabrina M Spano; Jasbir Kaur; Patrizia Casaccia; Diana Dow-Edwards; Yasmin L Hurd
Journal:  Biol Psychiatry       Date:  2011-08-05       Impact factor: 13.382

Review 9.  Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.

Authors:  Eun Yong Chung; Hye Jin Cha; Hyun Kyu Min; Jaesuk Yun
Journal:  Arch Pharm Res       Date:  2021-04-02       Impact factor: 4.946

10.  Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Authors:  Julie A Przybyla; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-12-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.